#United States #Sunnyvale #Cepheid #IMV Awards #Diagnostic Systems

Cepheid Celebrates Triple Win at 2026 IMV ServiceTrak Clinical Laboratory Awards

Cepheid, a notable name in molecular diagnostics and a subsidiary of Danaher, has achieved remarkable recognition at the 2026 IMV ServiceTrak Clinical Laboratory Awards, held during IDWeek. This event, significant within the medical community, highlighted Cepheid's outstanding contributions to the field by awarding the company in three categories: Clinical Laboratory Customer Satisfaction, Customer Service, and System Performance.

The IMV ServiceTrak Clinical Laboratory Awards are based on comprehensive feedback from professionals working in various clinical laboratories. This feedback is derived from two extensive interviews conducted across nearly 2,000 testing locations, representing over 4,000 diagnostic instruments. The awards serve as a reliable benchmark within the industry, assessing manufacturer performance in delivering real value and satisfaction to clinical laboratories.

This year’s accolades are particularly meaningful for Cepheid because they embody the trust and satisfaction expressed by laboratory professionals who utilize its GeneXpert® systems daily. Luke Maitland, the Senior Vice President and Chief Commercial Officer at Cepheid, expressed that these honors underscore the company’s commitment to developing innovative solutions that enable healthcare providers to access crucial diagnostic insights efficiently and effectively. He stated, “Winning the ServiceTrak™ Best of awards reflects real feedback from the clinical lab professionals who use Cepheid's GeneXpert systems every day.”

The true strength of Cepheid lies in its dedication to improving healthcare outcomes by providing timely, reliable diagnostics through its advanced technology and responsive service. The company’s slogan, “A Better Way,” encapsulates its mission to make complicated diagnostic processes simpler and quicker for institutions of all sizes. This year’s recognition reiterates that commitment, emphasizing how essential it is for healthcare teams to receive actionable answers promptly, especially in critical situations.

Richa Singh, Vice President of Strategic Insights at IMV, emphasized the importance of genuine feedback from laboratory professionals in determining these awards. She remarked, “These awards are grounded in independent, data-driven research, which makes them one of the most credible benchmarks in the industry.” This highlights the value of customer input in shaping the evolution of healthcare solutions and service standards.

Beyond these awards, Cepheid remains focused on expanding its broad portfolio of diagnostic tests that cover areas such as respiratory infections, blood virology, women’s and sexual health, tuberculosis, and emerging infectious diseases. The aim is to furnish healthcare settings, from large hospitals to smaller clinics, with the capacity to conduct world-class PCR testing that yields actionable results on-site. By striving to streamline and enhance diagnostic processes, Cepheid plays a pivotal role in supporting healthcare providers across the globe.

In summary, Cepheid’s recent trio of awards from the IMV ServiceTrak Program highlights not only its technological prowess but also its commitment to improving the healthcare ecosystem. These recognitions certainly set a high standard in the molecular diagnostics industry and reassure its clients and users of the firm’s dedication to ongoing innovation and customer satisfaction. The future looks bright for Cepheid as it continues to partner with healthcare professionals in meeting their evolving needs with agility, reliability, and unparalleled service.